Cardinal Health, Inc. (NYSE:CAH) Receives $266.56 Consensus Target Price from Analysts

Cardinal Health, Inc. (NYSE:CAH) has been assigned an average recommendation of “Moderate Buy” from the nineteen research firms that are currently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and sixteen have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $266.5625.

Several research analysts have recently weighed in on the company. Weiss Ratings cut Cardinal Health from a “buy (b+)” rating to a “buy (b)” rating in a research report on Wednesday. Morgan Stanley boosted their target price on Cardinal Health from $255.00 to $265.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. JPMorgan Chase & Co. upped their price target on Cardinal Health from $215.00 to $260.00 and gave the stock a “neutral” rating in a research report on Thursday, August 13th. Mizuho raised their price target on shares of Cardinal Health from $240.00 to $250.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 12th. Finally, Wells Fargo & Company lifted their price objective on shares of Cardinal Health from $245.00 to $277.00 and gave the company an “overweight” rating in a report on Wednesday, August 12th.

More Cardinal Health News

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Royal Bank of Canada initiated coverage with an “outperform” rating and a $276 price target, implying meaningful upside from recent trading levels. RBC cited Cardinal Health’s higher-margin services as a potential earnings-growth driver. RBC initiates coverage of Cardinal Health
• Positive Sentiment: Wall Street remains broadly constructive, with 16 analysts rating CAH a Buy and three assigning a Hold rating. The consensus rating is “Moderate Buy,” with an average price target of approximately $266.56. Zacks also identified Cardinal Health as a potentially attractive long-term value stock. Zacks value-stock analysis
• Positive Sentiment: Cardinal Health’s latest quarter delivered adjusted earnings per share of $2.91, well above the $2.42 consensus estimate, while revenue increased 5.8% year over year. Fiscal 2027 EPS guidance of $12.40–$12.60 supports the longer-term earnings case.
• Neutral Sentiment: The company declared a quarterly dividend of $0.5158 per share, equivalent to $2.06 annually and a yield of about 0.9%. The payout offers modest income support but is unlikely to be a major near-term catalyst.
• Negative Sentiment: Several executives sold sizable holdings around $235–$237 per share. CEO Jason Hollar sold 124,529 shares worth about $29.4 million, while other executive and insider sales—including those by Deborah Weitzman, Stephen Mason, Michelle Greene, Jessica Mayer and Mary Scherer—totaled roughly $20 million more. The concentrated selling and substantial reductions in insider ownership may encourage profit-taking concerns after CAH’s strong advance. Cardinal Health insider sales
• Negative Sentiment: Investors may also question the durability of the latest earnings beat because part of the improvement reportedly reflected a one-time tariff refund, potentially limiting the stock’s upside if recurring earnings growth does not match expectations. Cardinal Health earnings analysis

Insiders Place Their Bets

In other Cardinal Health news, CEO Deborah Weitzman sold 7,354 shares of Cardinal Health stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $235.45, for a total value of $1,731,499.30. Following the sale, the chief executive officer directly owned 77,901 shares in the company, valued at approximately $18,341,790.45. The trade was a 8.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Jason M. Hollar sold 80,000 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $235.74, for a total transaction of $18,859,200.00. Following the sale, the chief executive officer directly owned 235,132 shares in the company, valued at $55,430,017.68. This trade represents a 25.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 210,271 shares of company stock valued at $49,626,657 in the last quarter. Company insiders own 0.12% of the company’s stock.

Institutional Trading of Cardinal Health

Several institutional investors and hedge funds have recently bought and sold shares of the stock. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Cardinal Health during the 4th quarter worth approximately $26,000. Bank of Jackson Hole Trust acquired a new stake in shares of Cardinal Health in the 4th quarter valued at approximately $27,000. Jones Financial Companies Lllp boosted its holdings in shares of Cardinal Health by 198.3% in the 1st quarter. Jones Financial Companies Lllp now owns 21,112 shares of the company’s stock valued at $27,000 after buying an additional 14,034 shares during the last quarter. Palladiem LLC bought a new position in shares of Cardinal Health in the fourth quarter valued at $28,000. Finally, Indiana Trust & Investment Management Co bought a new position in shares of Cardinal Health in the first quarter valued at $29,000. Institutional investors own 87.17% of the company’s stock.

Cardinal Health Trading Up 0.4%

CAH opened at $229.48 on Thursday. The stock has a market capitalization of $53.37 billion, a P/E ratio of 31.74, a P/E/G ratio of 1.23 and a beta of 0.49. Cardinal Health has a 12 month low of $145.87 and a 12 month high of $258.30. The firm’s fifty day simple moving average is $232.02 and its 200 day simple moving average is $217.86.

Cardinal Health (NYSE:CAH) last announced its earnings results on Tuesday, August 11th. The company reported $2.91 earnings per share for the quarter, topping analysts’ consensus estimates of $2.42 by $0.49. Cardinal Health had a net margin of 0.67% and a negative return on equity of 98.53%. The firm had revenue of $63.67 billion during the quarter, compared to analyst estimates of $65.15 billion. During the same period in the prior year, the business earned $2.08 EPS. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. On average, equities research analysts predict that Cardinal Health will post 12.54 EPS for the current fiscal year.

Cardinal Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Thursday, October 1st will be given a $0.5158 dividend. The ex-dividend date of this dividend is Thursday, October 1st. This represents a $2.06 dividend on an annualized basis and a yield of 0.9%. Cardinal Health’s dividend payout ratio (DPR) is 28.49%.

About Cardinal Health

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.